- Previous Close
6.54 - Open
6.70 - Bid 6.53 x 100
- Ask 6.63 x 100
- Day's Range
6.40 - 7.14 - 52 Week Range
2.30 - 7.39 - Volume
2,443,419 - Avg. Volume
1,875,558 - Market Cap (intraday)
586.239M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.47 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
20.06
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
www.trevitherapeutics.comRecent News: TRVI
View More
Performance Overview: TRVI
Trailing total returns as of 3/18/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TRVI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TRVI
View MoreValuation Measures
Market Cap
586.24M
Enterprise Value
479.65M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.88
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-32.15%
Return on Equity (ttm)
-52.59%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-47.91M
Diluted EPS (ttm)
-0.47
Balance Sheet and Cash Flow
Total Cash (mrq)
107.62M
Total Debt/Equity (mrq)
1.04%
Levered Free Cash Flow (ttm)
-24.62M
Research Analysis: TRVI
View MoreCompany Insights: TRVI
TRVI does not have Company Insights